Siegel RL, Miller KD, Wagle NS, Jemal A. Most cancers statistics, 2023. CA Most cancers J Clin. 2023;73:17–48.
Ju W, Zheng R, Zhang S, Zeng H, Solar Ok, Wang S, Chen R, Li L, Wei W, He J. Most cancers statistics in Chinese language older individuals, 2022: present burden, time tendencies, and comparisons with the US, Japan, and the Republic of Korea. Sci China Life Sci. 2022. https://doi.org/10.1007/s11427-022-2218-x.
Rebello RJ, Oing C, Knudsen KE, Loeb S, Johnson DC, Reiter RE, Gillessen S, Van der Kwast T, Bristow RG. Prostate most cancers. Nat Rev Dis Primers. 2021;7:9.
Bandini M, Mazzone E, Preisser F, Nazzani S, Zaffuto E, Marchioni M, Tian Z, Pompe RS, Tilki D, Graefen M, et al. Enhance within the annual price of newly recognized metastatic prostate most cancers: a recent evaluation of the surveillance, epidemiology and finish outcomes database. Eur Urol Oncol. 2018;1:314–20.
Cary KC, Cooperberg MR. Biomarkers in prostate most cancers surveillance and screening: previous, current, and future. Ther Adv Urol. 2013;5:318–29.
Prensner JR, Rubin MA, Wei JT, Chinnaiyan AM. Past PSA: the subsequent technology of prostate most cancers biomarkers. Sci Transl Med. 2012;4:127rv123.
Medd JCC, Stockler MR, Collins R, Lalak A. Measuring males’s opinions of prostate needle biopsy. ANZ J Surg. 2005;75:662–4.
Schröder FH, Hugosson J, Roobol MJ, Tammela TLJ, Zappa M, Nelen V, Kwiatkowski M, Lujan M, Määttänen L, Lilja H, et al. Screening and prostate most cancers mortality: outcomes of the European randomised examine of screening for prostate most cancers (ERSPC) at 13 years of follow-up. Lancet. 2014;384:2027–35.
Etzioni R, Gulati R, Cooperberg MR, Penson DM, Weiss NS, Thompson IM. Limitations of basing screening insurance policies on screening trials: the US preventive providers job pressure and prostate most cancers screening. Med Care. 2013;51:295–300.
Cohen JD, Li L, Wang Y, Thoburn C, Afsari B, Danilova L, Douville C, Javed AA, Wong F, Mattox A, et al. Detection and localization of surgically resectable cancers with a multi-analyte blood check. Science. 2018;359:926–30.
Mellby LD, Nyberg AP, Johansen JS, Wingren C, Nordestgaard BG, Bojesen SE, Mitchell BL, Sheppard BC, Sears RC, Borrebaeck CAK. Serum biomarker signature-based liquid biopsy for prognosis of early-stage pancreatic most cancers. J Clin Oncol. 2018;36:2887–94.
De Rubis G, Rajeev Krishnan S, Bebawy M. Liquid biopsies in most cancers prognosis, monitoring, and prognosis. Traits Pharmacol Sci. 2019;40:172–86.
Fitts CA, Ji N, Li Y, Tan C. Exploiting exosomes in most cancers liquid biopsies and drug supply. Adv Healthc Mater. 2019;8:e1801268.
Chaffer CL, Weinberg RA. A perspective on most cancers cell metastasis. Science. 2011;331:1559–64.
Azmi AS, Bao B, Sarkar FH. Exosomes in most cancers improvement, metastasis, and drug resistance: a complete assessment. Most cancers Metastasis Rev. 2013;32:623–42.
Han Q-F, Li W-J, Hu Ok-S, Gao J, Zhai W-L, Yang J-H, Zhang S-J. Exosome biogenesis: equipment, regulation, and therapeutic implications in most cancers. Mol Most cancers. 2022;21:207.
Stuffers S, Sem Wegner C, Stenmark H, Brech A. Multivesicular endosome biogenesis within the absence of ESCRTs. Visitors. 2009;10:925–37.
Kenific CM, Zhang H, Lyden D. An exosome pathway with out an ESCRT. Cell Res. 2021;31:105–6.
Wei D, Zhan W, Gao Y, Huang L, Gong R, Wang W, Zhang R, Wu Y, Gao S, Kang T. RAB31 marks and controls an ESCRT-independent exosome pathway. Cell Res. 2021;31:157–77.
Juan T, Fürthauer M. Biogenesis and performance of ESCRT-dependent extracellular vesicles. Semin Cell Dev Biol. 2018;74:66–77.
Dong X, Bai X, Ni J, Zhang H, Duan W, Graham P, Li Y. Exosomes and breast most cancers drug resistance. Cell Loss of life Dis. 2020;11:987.
Gao Z, Pang B, Li J, Gao N, Fan T, Li Y. Rising position of exosomes in liquid biopsy for monitoring prostate most cancers invasion and metastasis. Entrance Cell Dev Biol. 2021;9:679527.
Wang J, Ni J, Beretov J, Thompson J, Graham P, Li Y. Exosomal microRNAs as liquid biopsy biomarkers in prostate most cancers. Crit Rev Oncol Hematol. 2020;145:102860.
Yang KS, Im H, Hong S, Pergolini I, del Castillo AF, Wang R, Clardy S, Huang C-H, Pille C, Ferrone S, et al. Multiparametric plasma EV profiling facilitates prognosis of pancreatic malignancy. Sci Transl Med. 2017;9:eaal3226.
Chen G, Huang AC, Zhang W, Zhang G, Wu M, Xu W, Yu Z, Yang J, Wang B, Solar H, et al. Exosomal PD-L1 contributes to immunosuppression and is related to anti-PD-1 response. Nature. 2018;560:382–6.
Jurj A, Pop-Bica C, Slaby O, Ştefan CD, Cho WC, Korban SS, Berindan-Neagoe I. tiny actors within the large mobile world: extracellular vesicles enjoying vital roles in most cancers. Int J Mol Sci. 2020;21:7688.
Wortzel I, Dror S, Kenific CM, Lyden D. Exosome-mediated metastasis: communication from a distance. Dev Cell. 2019;49:347–60.
Ulivi P, Indraccolo S. Liquid biopsies in most cancers prognosis monitoring and prognosis. Biomedicines. 2022;10:2748.
Paolini L, Zendrini A, Di Noto G, Busatto S, Lottini E, Radeghieri A, Dossi A, Caneschi A, Ricotta D, Bergese P. Residual matrix from completely different separation strategies impacts exosome organic exercise. Sci Rep. 2016;6:23550.
Chen B-Y, Sung CW-H, Chen C, Cheng C-M, Lin DP-C, Huang C-T, Hsu M-Y. Advances in exosomes know-how. Clinica Chimica Acta Int J Clin Chem. 2019;493:14–9.
Palviainen M, Laukkanen Ok, Tavukcuoglu Z, Velagapudi V, Kärkkäinen O, Hanhineva Ok, Auriola S, Ranki A, Siljander P. Most cancers alters the metabolic fingerprint of extracellular vesicles. Cancers. 2020;12:3292.
Sunkara V, Kim C-J, Park J, Woo H-Ok, Kim D, Ha HK, Kim M-H, Son Y, Kim J-R, Cho Y-Ok. Absolutely automated, label-free isolation of extracellular vesicles from entire blood for most cancers prognosis and monitoring. Theranostics. 2019;9:1851–63.
Bijnsdorp IV, Maxouri O, Kardar A, Schelfhorst T, Piersma SR, Pham TV, Vis A, van Moorselaar RJ, Jimenez CR. Feasibility of urinary extracellular vesicle proteome profiling utilizing a sturdy and easy, clinically relevant isolation methodology. J Extracell Vesicles. 2017;6:1313091.
Correll VL, Otto JJ, Risi CM, Predominant BP, Boutros PC, Kislinger T, Galkin VE, Nyalwidhe JO, Semmes OJ, Yang L. Optimization of small extracellular vesicle isolation from expressed prostatic secretions in urine for in-depth proteomic evaluation. J Extracell Vesicles. 2022;11:e12184.
Dhondt B, Geeurickx E, Tulkens J, Van Deun J, Vergauwen G, Lippens L, Miinalainen I, Rappu P, Heino J, Ost P, et al. Unravelling the proteomic panorama of extracellular vesicles in prostate most cancers by density-based fractionation of urine. J Extracell Vesicles. 2020;9:1736935.
Guan S, Yu H, Yan G, Gao M, Solar W, Zhang X. Characterization of urinary exosomes purified with dimension exclusion chromatography and ultracentrifugation. J Proteome Res. 2020;19:2217–25.
Brzozowski JS, Bond DR, Jankowski H, Goldie BJ, Burchell R, Naudin C, Smith ND, Scarlett CJ, Larsen MR, Dun MD, et al. Extracellular vesicles with altered tetraspanin CD9 and CD151 ranges confer elevated prostate cell motility and invasion. Sci Rep. 2018;8:8822.
Pang B, Zhu Y, Ni J, Ruan J, Thompson J, Malouf D, Bucci J, Graham P, Li Y. High quality evaluation and comparability of plasma-derived extracellular vesicles separated by three business kits for prostate most cancers prognosis. Int J Nanomedicine. 2020;15:10241–56.
García-Flores M, Sánchez-López CM, Ramírez-Calvo M, Fernández-Serra A, Marcilla A, López-Guerrero JA. Isolation and characterization of urine microvesicles from prostate most cancers sufferers: completely different approaches, completely different visions. BMC Urol. 2021;21:137.
Chen Y, Zhu Q, Cheng L, Wang Y, Li M, Yang Q, Hu L, Lou D, Li J, Dong X, et al. Exosome detection by way of the ultrafast-isolation system: EXODUS. Nat Strategies. 2021;18:212–8.
Morani M, Taverna M, Krupova Z, Alexandre L, Defrenaix P, Mai TD. Growth of a microfluidic droplet platform with an antibody-free magnetic-bead-based technique for top through-put and environment friendly EVs isolation. Talanta. 2022;249:123625.
Foroni C, Zarovni N, Bianciardi L, Bernardi S, Triggiani L, Zocco D, Venturella M, Chiesi A, Valcamonico F, Berruti A. When much less is extra: particular seize and evaluation of tumor exosomes in plasma will increase the sensitivity of liquid biopsy for complete detection of a number of androgen receptor phenotypes in superior prostate most cancers sufferers. Biomedicines. 2020;8:131.
Brett SI, Lucien F, Guo C, Williams KC, Kim Y, Durfee PN, Brinker CJ, Chin JI, Yang J, Leong HS. Immunoaffinity primarily based strategies are superior to kits for purification of prostate derived extracellular vesicles from plasma samples. Prostate. 2017;77:1335–43.
Patel GK, Khan MA, Zubair H, Srivastava SK, Khushman Md, Singh S, Singh AP. Comparative evaluation of exosome isolation strategies utilizing tradition supernatant for optimum yield, purity and downstream functions. Sci Rep. 2019;9:5335.
Shtam T, Evtushenko V, Samsonov R, Zabrodskaya Y, Kamyshinsky R, Zabegina L, Verlov N, Burdakov V, Garaeva L, Slyusarenko M, et al. Analysis of immune and chemical precipitation strategies for plasma exosome isolation. PLoS ONE. 2020;15:e0242732.
Dong L, Zieren RC, Horie Ok, Kim C-J, Mallick E, Jing Y, Feng M, Kuczler MD, Inexperienced J, Amend SR, et al. Complete analysis of strategies for small extracellular vesicles separation from human plasma, urine and cell tradition medium. J Extracell Vesicles. 2020;10:e12044.
Wang C-B, Chen S-H, Zhao L, Jin X, Chen X, Ji J, Mo Z-N, Wang F-B. Urine-derived exosomal PSMA is a promising diagnostic biomarker for the detection of prostate most cancers on preliminary biopsy. Clin Transl Oncol. 2023;25:758–67.
Li Y, Ji J, Lyu J, Jin X, He X, Mo S, Xu H, He J, Cao Z, Chen X, et al. A novel urine exosomal lncRNA assay to enhance the detection of prostate most cancers at preliminary biopsy: a retrospective multicenter diagnostic feasibility examine. Cancers. 2021;13:4075.
Mercadal M, Herrero C, López-Rodrigo O, Castells M, de la Fuente A, Vigués F, Bassas L, Larriba S. Impression of extracellular vesicle isolation strategies on downstream mirna evaluation in semen: a comparative examine. Int J Mol Sci. 2020;21:5949.
Lin S, Yu Z, Chen D, Wang Z, Miao J, Li Q, Zhang D, Tune J, Cui D. Progress in microfluidics-based exosome separation and detection applied sciences for diagnostic functions. Small. 2020;16:e1903916.
Li Q, Wang Y, Xue Y, Qiao L, Yu G, Liu Y, Yu S. Ultrasensitive evaluation of exosomes utilizing a 3D Self-assembled nanostructured SiO2 microfluidic chip. ACS Appl Mater Interfaces. 2022;14:14693–702.
Ku A, Fredsøe J, Sørensen KD, Borre M, Evander M, Laurell T, Lilja H, Ceder Y. Excessive-throughput and automatic acoustic trapping of extracellular vesicles to establish microRNAs with diagnostic potential for prostate most cancers. Entrance Oncol. 2021;11:631021.
Kang Y-T, Kim YJ, Bu J, Cho Y-H, Han S-W, Moon B-I. Excessive-purity seize and launch of circulating exosomes utilizing an exosome-specific dual-patterned immunofiltration (ExoDIF) system. Nanoscale. 2017;9:13495–505.
Koh YQ, Almughlliq FB, Vaswani Ok, Peiris HN, Mitchell MD. Exosome enrichment by ultracentrifugation and dimension exclusion chromatography. Entrance Biosci (Landmark Ed). 2018;23:865–74.
Lee H, Kang SJ, Lee J, Park KH, Rhee WJ. Isolation and characterization of urinary extracellular vesicles from wholesome donors and sufferers with castration-resistant prostate most cancers. Int J Mol Sci. 2022;23:7134.
Solar N, Tran BV, Peng Z, Wang J, Zhang C, Yang P, Zhang TX, Widjaja J, Zhang RY, Xia W, et al. Coupling lipid labeling and click on chemistry allows isolation of extracellular vesicles for noninvasive detection of oncogenic gene alterations. Adv Sci (Weinh). 2022;9:e2105853.
Yoshida T, Hanayama R. TIM4-Affinity strategies concentrating on phosphatidylserine for isolation or detection of extracellular vesicles. Strategies Mol Biol. 2022;2466:23–36.
Liu H-Y, Kumar R, Zhong C, Gorji S, Paniushkina L, Masood R, Wittel UA, Fuchs H, Nazarenko I, Hirtz M. Speedy seize of most cancers extracellular vesicles by lipid patch microarrays. Adv Mater. 2021;33:e2008493.
Petersen KE, Shiri F, White T, Bardi GT, Sant H, Gale BK, Hood JL. Exosome isolation: cyclical electrical area movement fractionation in low-ionic-strength fluids. Anal Chem. 2018;90:12783–90.
Gao Z, Hutchins Z, Li Z, Zhong W. Offline coupling of asymmetrical movement field-flow fractionation and capillary electrophoresis for separation of extracellular vesicles. Anal Chem. 2022;94:14083–91.
Bryzgunova OE, Zaripov MM, Skvortsova TE, Lekchnov EA, Grigor’eva AE, Zaporozhchenko IA, Morozkin ES, Ryabchikova EI, Yurchenko YB, Voitsitskiy VE, Laktionov PP. Comparative examine of extracellular vesicles from the urine of wholesome people and prostate most cancers sufferers. PLOS ONE. 2016;11:e0157566.
Rood IM, Deegens JKJ, Service provider ML, Tamboer WPM, Wilkey DW, Wetzels JFM, Klein JB. Comparability of three strategies for isolation of urinary microvesicles to establish biomarkers of nephrotic syndrome. Kidney Int. 2010;78:810–6.
Lewis JM, Vyas AD, Qiu Y, Messer KS, White R, Heller MJ. Built-in evaluation of exosomal protein biomarkers on alternating present electrokinetic chips allows fast detection of pancreatic most cancers in affected person blood. ACS Nano. 2018;12:3311–20.
Théry C, Witwer KW, Aikawa E, Alcaraz MJ, Anderson JD, Andriantsitohaina R, Antoniou A, Arab T, Archer F, Atkin-Smith GK, et al. Minimal info for research of extracellular vesicles 2018 (MISEV2018): a place assertion of the worldwide society for extracellular vesicles and replace of the MISEV2014 tips. J Extracell Vesicles. 2018;7:1535750.
Schey KL, Luther JM, Rose KL. Proteomics characterization of exosome cargo. Strategies. 2015;87:75–82.
Crescitelli R, Lässer C, Jang SC, Cvjetkovic A, Malmhäll C, Karimi N, Höög JL, Johansson I, Fuchs J, Thorsell A, et al. Subpopulations of extracellular vesicles from human metastatic melanoma tissue recognized by quantitative proteomics after optimized isolation. J Extracell Vesicles. 2020;9:1722433.
Rupert DLM, Lässer C, Eldh M, Block S, Zhdanov VP, Lotvall JO, Bally M, Höök F. Dedication of exosome focus in resolution utilizing floor plasmon resonance spectroscopy. Anal Chem. 2014;86:5929–36.
Liu C, Zeng X, An Z, Yang Y, Eisenbaum M, Gu X, Jornet JM, Dy GK, Reid ME, Gan Q, Wu Y. Delicate detection of exosomal proteins by way of a compact floor plasmon resonance biosensor for most cancers prognosis. ACS Sens. 2018;3:1471–9.
Li M, Xi N, Wang Y-C, Liu L-Q. Atomic pressure microscopy for revealing micro/nanoscale mechanics in tumor metastasis: from single cells to microenvironmental cues. Acta Pharmacol Sin. 2021;42:323–39.
Corso G, Heusermann W, Trojer D, Görgens A, Steib E, Voshol J, Graff A, Genoud C, Lee Y, Hean J, et al. Systematic characterization of extracellular vesicle sorting domains and quantification on the single molecule – single vesicle degree by fluorescence correlation spectroscopy and single particle imaging. J Extracell Vesicles. 2019;8:1663043.
Fisher WS, Tchounwou C, Wei S, Roberts L, Ewert KK, Safinya CR. Exosomes are secreted at related densities by M21 and PC3 human most cancers cells and present paclitaxel solubility. Biochim Biophys Acta Biomembr. 2022;1864:183841.
Bertokova A, Svecova N, Kozics Ok, Gabelova A, Vikartovska A, Jane E, Hires M, Bertok T, Tkac J. Exosomes from prostate most cancers cell strains: Isolation optimisation and characterisation. Biomed Pharmacother. 2022;151:113093.
Choi WWY, Sánchez C, Li JJ, Dinarvand M, Adomat H, Ghaffari M, Khoja L, Vafaee F, Joshua AM, Chi KN, et al. Extracellular vesicles from organic fluids as potential markers in castration resistant prostate most cancers. J Most cancers Res Clin Oncol. 2022. https://doi.org/10.1007/s00432-022-04391-6.
Ma Q, Liang M, Wu Y, Dou C, Xu J, Dong S, Luo F. Small extracellular vesicles ship osteolytic effectors and mediate cancer-induced osteolysis in bone metastatic area of interest. J Extracell Vesicles. 2021;10:e12068.
Linxweiler J, Kolbinger A, Himbert D, Zeuschner P, Saar M, Stöckle M, Junker Ok. Organ-specific uptake of extracellular vesicles secreted by urological most cancers cells. Cancers. 2021;13:4937.
Chen Ok, Wang Q, Liu X, Wang F, Yang Y, Tian X. Hypoxic pancreatic most cancers derived exosomal miR-30b-5p promotes tumor angiogenesis by inhibiting GJA1 expression. Int J Biol Sci. 2022;18:1220–37.
Todorova D, Simoncini S, Lacroix R, Sabatier F, Dignat-George F. Extracellular vesicles in angiogenesis. Circ Res. 2017;120:1658–73.
Whiteside TL. Tumor-derived exosomes and their position in tumor-induced immune suppression. Vaccines. 2016;4:35.
Tai Y-L, Chen Ok-C, Hsieh J-T, Shen T-L. Exosomes in most cancers improvement and medical functions. Most cancers Sci. 2018;109:2364–74.
Mashouri L, Yousefi H, Aref AR, Ahadi AM, Molaei F, Alahari SK. Exosomes: composition, biogenesis, and mechanisms in most cancers metastasis and drug resistance. Mol Most cancers. 2019;18:75.
Pastushenko I, Blanpain C. EMT transition states throughout tumor development and metastasis. Traits Cell Biol. 2019;29:212–26.
Gaballa R, Ali HEA, Mahmoud MO, Rhim JS, Ali HI, Salem HF, Saleem M, Kandeil MA, Ambs S, Abd Elmageed ZY. Exosomes-mediated switch of Itga2 promotes migration and invasion of prostate most cancers cells by inducing epithelial-mesenchymal transition. Cancers. 2020;12:2300.
Li Y, Li Q, Li D, Gu J, Qian D, Qin X, Chen Y. Exosome carrying PSGR promotes stemness and epithelial-mesenchymal transition of low aggressive prostate most cancers cells. Life Sci. 2021;264:118638.
Miyazaki T, Ikeda Ok, Sato W, Horie-Inoue Ok, Inoue S. Extracellular vesicle-mediated EBAG9 switch from most cancers cells to tumor microenvironment promotes immune escape and tumor development. Oncogenesis. 2018;7:7.
Lin C-J, Yun E-J, Lo UG, Tai Y-L, Deng S, Hernandez E, Dang A, Chen Y-A, Saha D, Mu P, et al. The paracrine induction of prostate most cancers development by caveolin-1. Cell Loss of life Dis. 2019;10:834.
Ronquist KG, Sanchez C, Dubois L, Chioureas D, Fonseca P, Larsson A, Ullén A, Yachnin J, Ronquist G, Panaretakis T. Vitality-requiring uptake of prostasomes and PC3 cell-derived exosomes into non-malignant and malignant cells. J Extracell Vesicles. 2016;5:29877.
Learn J, Ingram A, Al Saleh HA, Platko Ok, Gabriel Ok, Kapoor A, Pinthus J, Majeed F, Qureshi T, Al-Nedawi Ok. Nuclear transportation of exogenous epidermal progress issue receptor and androgen receptor by way of extracellular vesicles. Eur J Most cancers. 2017;70:62–74.
Tian H-Y, Liang Q, Shi Z, Zhao H. Exosomal CXCL14 contributes to M2 macrophage polarization by way of NF-κB signaling in prostate most cancers. Oxid Med Cell Longev. 2022;2022:7616696.
Fontana F, Anselmi M, Carollo E, Sartori P, Procacci P, Carter D, Limonta P. Adipocyte-derived extracellular vesicles promote prostate most cancers cell aggressiveness by enabling a number of phenotypic and metabolic modifications. Cells. 2022;11:2388.
Yang C, Guo WB, Zhang WS, Bian J, Yang JK, Zhou QZ, Chen MK, Peng W, Qi T, Wang CY, Liu CD. Complete proteomics evaluation of exosomes derived from human seminal plasma. Andrology. 2017;5:1007–15.
Basu A. The interaction between apoptosis and mobile senescence: Bcl-2 household proteins as targets for most cancers remedy. Pharmacol Ther. 2022;230:107943.
Che Y, Shi X, Shi Y, Jiang X, Ai Q, Shi Y, Gong F, Jiang W. Exosomes derived from miR-143-overexpressing MSCs inhibit cell migration and invasion in human prostate most cancers by downregulating TFF3. Mol Ther Nucleic Acids. 2019;18:232–44.
Lehmann BD, Paine MS, Brooks AM, McCubrey JA, Renegar RH, Wang R, Terrian DM. Senescence-associated exosome launch from human prostate most cancers cells. Most cancers Res. 2008;68:7864–71.
Chowdhury SG, Ray R, Bhattacharya D, Karmakar P. DNA injury induced mobile senescence and it’s PTEN-armed exosomes-the warriors in opposition to prostate carcinoma cells. Med Oncol. 2022;39:34.
Jiang X, Wang J, Deng X, Xiong F, Zhang S, Gong Z, Li X, Cao Ok, Deng H, He Y, et al. The position of microenvironment in tumor angiogenesis. J Exp Clin Most cancers Res. 2020;39:204.
Krishn SR, Salem I, Quaglia F, Naranjo NM, Agarwal E, Liu Q, Sarker S, Kopenhaver J, McCue PA, Weinreb PH, et al. The αvβ6 integrin in most cancers cell-derived small extracellular vesicles enhances angiogenesis. J Extracell Vesicles. 2020;9:1763594.
DeRita RM, Zerlanko B, Singh A, Lu H, Iozzo RV, Benovic JL, Languino LR. c-Src, Insulin-like progress issue I receptor, G-protein-coupled receptor kinases and focal adhesion kinase are enriched into prostate most cancers cell exosomes. J Cell Biochem. 2017;118:66–73.
Liu P, Wang W, Wang F, Fan J, Guo J, Wu T, Lu D, Zhou Q, Liu Z, Wang Y, et al. Alterations of plasma exosomal proteins and motabolies are related to the development of castration-resistant prostate most cancers. J Transl Med. 2023;21:40.
Ojalill M, Virtanen N, Rappu P, Siljamäki E, Taimen P, Heino J. Interplay between prostate most cancers cells and prostate fibroblasts promotes accumulation and proteolytic processing of basement membrane proteins. Prostate. 2020;80:715–26.
Bedeschi M, Marino N, Cavassi E, Piccinini F, Tesei A. Most cancers-associated fibroblast: position in prostate most cancers development to metastatic illness and therapeutic resistance. Cells. 2023;12:802.
Webber JP, Spary LK, Sanders AJ, Chowdhury R, Jiang WG, Steadman R, Wymant J, Jones AT, Kynaston H, Mason MD, et al. Differentiation of tumour-promoting stromal myofibroblasts by most cancers exosomes. Oncogene. 2015;34:290–302.
Halin Bergström S, Hägglöf C, Thysell E, Bergh A, Wikström P, Lundholm M. Extracellular vesicles from metastatic rat prostate tumors prime the conventional prostate tissue to facilitate tumor progress. Sci Rep. 2016;6:31805.
Sadovska L, Zayakin P, Bajo-Santos C, Endzeliņš E, Auders J, Keiša L, Jansons J, Lietuvietis V, Linē A. Results of urinary extracellular vesicles from prostate most cancers sufferers on the transcriptomes of cancer-associated and regular fibroblasts. BMC Most cancers. 2022;22:1055.
Zhang Z, Li X, Wang Y, Wei Y, Wei X. Involvement of inflammasomes in tumor microenvironment and tumor therapies. J Hematol Oncol. 2023;16:24.
Xu Z, Wang H, Qin Z, Zhao F, Zhou L, Xu L, Jia R. NLRP3 inflammasome promoted the malignant development of prostate most cancers by way of the activation of caspase-1. Cell Loss of life Discov. 2021;7:399.
Mezzasoma L, Talesa VN, Costanzi E, Bellezza I. Natriuretic peptides regulate prostate cells inflammatory habits: potential novel anticancer brokers for prostate most cancers. Biomolecules. 2021;11:794.
Panigrahi GK, Praharaj PP, Kittaka H, Mridha AR, Black OM, Singh R, Mercer R, van Bokhoven A, Torkko KC, Agarwal C, et al. Exosome proteomic analyses establish inflammatory phenotype and novel biomarkers in African American prostate most cancers sufferers. Most cancers Med. 2019;8:1110–23.
Urabe F, Patil Ok, Ramm GA, Ochiya T, Soekmadji C. Extracellular vesicles within the improvement of organ-specific metastasis. J Extracell Vesicles. 2021;10:e12125.
Lu H, Bowler N, Harshyne LA, Craig Hooper D, Krishn SR, Kurtoglu S, Fedele C, Liu Q, Tang H-Y, Kossenkov AV, et al. Exosomal αvβ6 integrin is required for monocyte M2 polarization in prostate most cancers. Matrix Biol. 2018;70:20–35.
Borel M, Lollo G, Magne D, Buchet R, Brizuela L, Mebarek S. Prostate cancer-derived exosomes promote osteoblast differentiation and exercise by way of phospholipase D2. Biochim Biophys Acta Mol Foundation Dis. 2020;1866:165919.
Shi Y, Pu Ok, Yao H, Chen Y, Zheng X, Zhao L, Ma X, Ge C. Gold nanorods inhibit tumor metastasis by regulating MMP-9 exercise: implications for radiotherapy. ACS Appl Mater Interfaces. 2023. https://doi.org/10.1021/acsami.2c20944.
Deep G, Jain A, Kumar A, Agarwal C, Kim S, Leevy WM, Agarwal R. Exosomes secreted by prostate most cancers cells underneath hypoxia promote matrix metalloproteinases exercise at pre-metastatic niches. Mol Carcinog. 2020;59:323–32.
Henrich SE, McMahon KM, Plebanek MP, Calvert AE, Feliciano TJ, Parrish S, Tavora F, Mega A, De Souza A, Carneiro BA, Thaxton CS. Prostate most cancers extracellular vesicles mediate intercellular communication with bone marrow cells and promote metastasis in a cholesterol-dependent method. J Extracell Vesicles. 2020;10:e12042.
Dai J, Escara-Wilke J, Keller JM, Jung Y, Taichman RS, Pienta KJ, Keller ET. Major prostate most cancers educates bone stroma by way of exosomal pyruvate kinase M2 to advertise bone metastasis. J Exp Med. 2019;216:2883–99.
Li D, Xia L, Huang P, Wang Z, Guo Q, Huang C, Leng W, Qin S. Heterogeneity and plasticity of epithelial-mesenchymal transition (EMT) in most cancers metastasis: specializing in partial EMT and regulatory mechanisms. Cell Prolif. 2023;56:e13423.
Voglstaetter M, Thomsen AR, Nouvel J, Koch A, Jank P, Navarro EG, Gainey-Schleicher T, Khanduri R, Groß A, Rossner F, et al. Tspan8 is expressed in breast most cancers and regulates E-cadherin/catenin signalling and metastasis accompanied by elevated circulating extracellular vesicles. J Pathol. 2019;248:421–37.
Liu J, Wu Q, Wang Y, Wei Y, Wu H, Duan L, Zhang Q, Wu Y. Ovol2 induces mesenchymal-epithelial transition by way of concentrating on ZEB1 in osteosarcoma. Onco Targets Ther. 2018;11:2963–73.
Yu L, Sui B, Fan W, Lei L, Zhou L, Yang L, Diao Y, Zhang Y, Li Z, Liu J, Hao X. Exosomes derived from osteogenic tumor activate osteoclast differentiation and concurrently inhibit osteogenesis by transferring COL1A1-targeting miRNA-92a-1-5p. J Extracell Vesicles. 2021;10:e12056.
Urabe F, Kosaka N, Yamamoto Y, Ito Ok, Otsuka Ok, Soekmadji C, Egawa S, Kimura T, Ochiya T. Metastatic prostate cancer-derived extracellular vesicles facilitate osteoclastogenesis by transferring the CDCP1 protein. J Extracell Vesicles. 2023;12:e12312.
Yang Q, Xu J, Gu J, Shi H, Zhang J, Zhang J, Chen Z-S, Fang X, Zhu T, Zhang X. Extracellular vesicles in most cancers drug resistance: roles, mechanisms, and implications. Adv Sci (Weinh). 2022;9:e2201609.
Cui X, Fu Q, Wang X, Xia P, Cui X, Bai X, Lu Z. Molecular mechanisms and medical functions of exosomes in prostate most cancers. Biomark Res. 2022;10:56.
Bhagirath D, Yang TL, Tabatabai ZL, Majid S, Dahiya R, Tanaka Y, Saini S. BRN4 Is a novel driver of neuroendocrine differentiation in castration-resistant prostate most cancers and is selectively launched in extracellular vesicles with BRN2. Clin Most cancers Res. 2019;25:6532–45.
Peak TC, Panigrahi GK, Praharaj PP, Su Y, Shi L, Chyr J, Rivera-Chávez J, Flores-Bocanegra L, Singh R, Vander Griend DJ, et al. Syntaxin 6-mediated exosome secretion regulates enzalutamide resistance in prostate most cancers. Mol Carcinog. 2020;59:62–72.
Lee H-C, Ou C-H, Huang Y-C, Hou P-C, Creighton CJ, Lin Y-S, Hu C-Y, Lin S-C. YAP1 overexpression contributes to the event of enzalutamide resistance by induction of most cancers stemness and lipid metabolism in prostate most cancers. Oncogene. 2021;40:2407–21.
Kharaziha P, Chioureas D, Rutishauser D, Baltatzis G, Lennartsson L, Fonseca P, Azimi A, Hultenby Ok, Zubarev R, Ullén A, et al. Molecular profiling of prostate most cancers derived exosomes could reveal a predictive signature for response to docetaxel. Oncotarget. 2015;6:21740–54.
Kato T, Mizutani Ok, Kameyama Ok, Kawakami Ok, Fujita Y, Nakane Ok, Kanimoto Y, Ehara H, Ito H, Seishima M, et al. Serum exosomal P-glycoprotein is a possible marker to diagnose docetaxel resistance and choose a taxoid for sufferers with prostate most cancers. Urol Oncol. 2015;33:385.e315-385.e320.
Greening DW, Xu R, Ale A, Hagemeyer CE, Chen W. Extracellular vesicles as subsequent technology immunotherapeutics. Semin Most cancers Biol. 2023. https://doi.org/10.1016/j.semcancer.2023.02.002.
Lundholm M, Schröder M, Nagaeva O, Baranov V, Widmark A, Mincheva-Nilsson L, Wikström P. Prostate tumor-derived exosomes down-regulate NKG2D expression on pure killer cells and CD8+ T cells: mechanism of immune evasion. PLoS ONE. 2014;9:e108925.
Salimu J, Webber J, Gurney M, Al-Taei S, Clayton A, Tabi Z. Dominant immunosuppression of dendritic cell perform by prostate-cancer-derived exosomes. J Extracell Vesicles. 2017;6:1368823.
Li N, Wang Y, Xu H, Wang H, Gao Y, Zhang Y. Exosomes derived from RM-1 cells promote the recruitment of MDSCs into tumor microenvironment by upregulating CXCR4 by way of TLR2/NF-κB pathway. J Oncol. 2021;2021:5584406.
Chen X, Li J, Zhang R, Zhang Y, Wang X, Leung EL-H, Ma L, Wong VKW, Liu L, Neher E, Yu H. Suppression of PD-L1 launch from small extracellular vesicles promotes systemic anti-tumor immunity by concentrating on ORAI1 calcium channels. J Extracell Vesicles. 2022;11:e12279.
Liu J, He D, Cheng L, Huang C, Zhang Y, Rao X, Kong Y, Li C, Zhang Z, Liu J, et al. p300/CBP inhibition enhances the efficacy of programmed death-ligand 1 blockade therapy in prostate most cancers. Oncogene. 2020;39:3939–51.
Zhang L, Yu D. Exosomes in most cancers improvement, metastasis, and immunity. Biochim Biophys Acta Rev Most cancers. 2019;1871:455–68.
Keerthikumar S, Chisanga D, Ariyaratne D, Saffar H, Anand S, Zhao KN, Samuel M, Pathan M, Jois M, Chilamkurti N, et al. ExoCarta: a web-based compendium of exosomal cargo. J Mol Biol. 2016;428:688–92.
Bhagirath D, Liston M, Akoto T, Lui B, Bensing BA, Sharma A, Saini S. Novel, non-invasive markers for detecting remedy induced neuroendocrine differentiation in castration-resistant prostate most cancers sufferers. Sci Rep. 2021;11:8279.
Ishizuya Y, Uemura M, Narumi R, Tomiyama E, Koh Y, Matsushita M, Nakano Ok, Hayashi Y, Wang C, Kato T, et al. The position of actinin-4 (ACTN4) in exosomes as a possible novel therapeutic goal in castration-resistant prostate most cancers. Biochem Biophys Res Commun. 2020;523:588–94.
Worst TS, von Hardenberg J, Gross JC, Erben P, Schnölzer M, Hausser I, Bugert P, Michel MS, Boutros M. Database-augmented mass spectrometry evaluation of exosomes identifies claudin 3 as a putative prostate most cancers biomarker. Mol Cell Proteomics. 2017;16:998–1008.
Park YH, Shin HW, Jung AR, Kwon OS, Choi Y-J, Park J, Lee JY. Prostate-specific extracellular vesicles as a novel biomarker in human prostate most cancers. Sci Rep. 2016;6:30386.
Vardaki I, Corn P, Gentile E, Tune JH, Madan N, Hoang A, Parikh N, Guerra L, Lee Y-C, Lin S-C, et al. Radium-223 therapy will increase immune checkpoint expression in extracellular vesicles from the metastatic prostate most cancers bone microenvironment. Clin Most cancers Res. 2021;27:3253–64.
Khanna Ok, Salmond N, Lynn KS, Leong HS, Williams KC. Scientific significance of STEAP1 extracellular vesicles in prostate most cancers. Prostate Most cancers Prostatic Dis. 2021;24:802–11.
Logozzi M, Mizzoni D, Capasso C, Del Prete S, Di Raimo R, Falchi M, Angelini DF, Sciarra A, Maggi M, Supuran CT, Fais S. Plasmatic exosomes from prostate most cancers sufferers present elevated carbonic anhydrase IX expression and exercise and low pH. J Enzyme Inhib Med Chem. 2020;35:280–8.
Krishn SR, Singh A, Bowler N, Duffy AN, Friedman A, Fedele C, Kurtoglu S, Tripathi SK, Wang Ok, Hawkins A, et al. Prostate most cancers sheds the αvβ3 integrin in vivo by way of exosomes. Matrix Biol. 2019;77:41–57.
Chung J-W, Kim HT, Ha Y-S, Lee EH, Chun SY, Lee C-H, Byeon KH, Choi SH, Lee JN, Kim BS, et al. Identification of a novel non-invasive organic marker to beat the shortcomings of PSA in prognosis and danger stratification for prostate most cancers: preliminary potential examine of developmental endothelial locus-1 protein. PLoS ONE. 2021;16:e0250254.
Li S, Zhao Y, Chen W, Yin L, Zhu J, Zhang H, Cai C, Li P, Huang L, Ma P. Exosomal ephrinA2 derived from serum as a possible biomarker for prostate most cancers. J Most cancers. 2018;9:2659–65.
Kawakami Ok, Fujita Y, Matsuda Y, Arai T, Horie Ok, Kameyama Ok, Kato T, Masunaga Ok, Kasuya Y, Tanaka M, et al. Gamma-glutamyltransferase exercise in exosomes as a possible marker for prostate most cancers. BMC Most cancers. 2017;17:316.
Fujita Ok, Kume H, Matsuzaki Ok, Kawashima A, Ujike T, Nagahara A, Uemura M, Miyagawa Y, Tomonaga T, Nonomura N. Proteomic evaluation of urinary extracellular vesicles from excessive gleason rating prostate most cancers. Sci Rep. 2017;7:42961.
Zhang H, Zhang G-Y, Su W-C, Chen Y-T, Liu Y-F, Wei D, Zhang Y-X, Tang Q-Y, Liu Y-X, Wang S-Z, et al. Excessive throughput isolation and information unbiased acquisition mass spectrometry (DIA-MS) of urinary extracellular vesicles to enhance prostate most cancers prognosis. Molecules. 2022;27:8155.
Boukouris S, Mathivanan S. Exosomes in bodily fluids are a extremely steady useful resource of illness biomarkers. Proteomics Clin Appl. 2015;9:358–67.
Saari H, Lázaro-Ibáñez E, Viitala T, Vuorimaa-Laukkanen E, Siljander P, Yliperttula M. Microvesicle- and exosome-mediated drug supply enhances the cytotoxicity of paclitaxel in autologous prostate most cancers cells. J Management Launch. 2015;220:727–37.
Wang D, Wan Z, Yang Q, Chen J, Liu Y, Lu F, Tang J. Sonodynamical reversion of immunosuppressive microenvironment in prostate most cancers by way of engineered exosomes. Drug Deliv. 2022;29:702–13.
Lee JH, Tune J, Kim IG, You G, Kim H, Ahn J-H, Mok H. Exosome-mediated supply of remodeling progress factor-β receptor 1 kinase inhibitors and toll-like receptor 7/8 agonists for mixture remedy of tumors. Acta Biomater. 2022;141:354–63.
Luo Z-W, Xia Ok, Liu Y-W, Liu J-H, Rao S-S, Hu X-Ok, Chen C-Y, Xu R, Wang Z-X, Xie H. Extracellular vesicles from akkermansia muciniphila elicit antitumor immunity in opposition to prostate most cancers by way of modulation of CD8+ T cells and macrophages. Int J Nanomedicine. 2021;16:2949–63.
Kurniawati I, Liu M-C, Hsieh C-L, Do AD, Sung S-Y. Concentrating on castration-resistant prostate most cancers utilizing mesenchymal stem cell exosomes for therapeutic MicroRNA-let-7c supply. Entrance Biosci (Landmark Ed). 2022;27:256.
Koh E, Lee EJ, Nam G-H, Hong Y, Cho E, Yang Y, Kim I-S. Exosome-SIRPα, a CD47 blockade will increase most cancers cell phagocytosis. Biomaterials. 2017;121:121–9.
Shin JM, Lee C-H, Son S, Kim CH, Lee JA, Ko H, Shin S, Tune SH, Park S-S, Bae J-H, et al. Sulfisoxazole elicits sturdy antitumour immune response together with immune checkpoint remedy by inhibiting exosomal PD-L1. Adv Sci (Weinh). 2022;9:e2103245.
Chen S, Zhu G, Yang Y, Wang F, Xiao Y-T, Zhang N, Bian X, Zhu Y, Yu Y, Liu F, et al. Single-cell evaluation reveals transcriptomic remodellings in distinct cell varieties that contribute to human prostate most cancers development. Nat Cell Biol. 2021;23:87–98.
Shi F, Solar M-H, Zhou Z, Wu L, Zhu Z, Xia S-J, Han B-M, Zhao Y-Y, Jing Y-F, Cui D. Tumor-associated macrophages in direct contact with prostate most cancers cells promote malignant proliferation and metastasis by way of NOTCH1 pathway. Int J Biol Sci. 2022;18:5994–6007.
Cui Z, Li W, Wang Y, Zhao M, Liu Ok, Yang Y, Teng S, Zhang N, Min L, Li P, et al. M2 macrophage-derived exosomal ferritin heavy chain promotes colon most cancers cell proliferation. Biol Hint Elem Res. 2022. https://doi.org/10.1007/s12011-022-03488-w.
Tanimoto T, Hori A, Kami M. Sipuleucel-T immunotherapy for castration-resistant prostate most cancers. New Engl J Med. 2010;363:1966 (1966; writer reply 1967-1966; writer reply 1968).
Zuo B, Zhang Y, Zhao Ok, Wu L, Qi H, Yang R, Gao X, Geng M, Wu Y, Jing R, et al. Common immunotherapeutic technique for hepatocellular carcinoma with exosome vaccines that have interaction adaptive and innate immune responses. J Hematol Oncol. 2022;15:46.
Rountree RB, Mandl SJ, Nachtwey JM, Dalpozzo Ok, Do L, Lombardo JR, Schoonmaker PL, Brinkmann Ok, Dirmeier U, Laus R, Delcayre A. Exosome concentrating on of tumor antigens expressed by most cancers vaccines can enhance antigen immunogenicity and therapeutic efficacy. Most cancers Res. 2011;71:5235–44.
Shi X, Solar J, Li H, Lin H, Xie W, Li J, Tan W. Antitumor efficacy of interferon-γ-modified exosomal vaccine in prostate most cancers. Prostate. 2020;80:811–23.
Rathi N, McFarland TR, Nussenzveig R, Agarwal N, Swami U. Evolving position of immunotherapy in metastatic castration refractory prostate most cancers. Medication. 2021;81:191–206.
Mentink A, Isebia KT, Kraan J, Terstappen LWMM, Stevens M. Measuring antigen expression of most cancers cell strains and circulating tumour cells. Sci Rep. 2023;13:6051.
Es-Haghi M, Neustroeva O, Chowdhury I, Laitinen P, Väänänen M-A, Korvenlaita N, Malm T, Turunen MP, Turunen TA. Building of fusion protein for enhanced small RNA loading to extracellular vesicles. Genes. 2023;14:261.
Hung ME, Leonard JN. A platform for actively loading cargo RNA to elucidate limiting steps in EV-mediated supply. J Extracell Vesicles. 2016;5:31027.
Pan S, Zhang Y, Huang M, Deng Z, Zhang A, Pei L, Wang L, Zhao W, Ma L, Zhang Q, Cui D. Urinary exosomes-based engineered nanovectors for homologously focused chemo-chemodynamic prostate most cancers remedy by way of abrogating EGFR/AKT/NF-kB/IkB signaling. Biomaterials. 2021;275:120946.
Altanerova U, Babincova M, Babinec P, Benejova Ok, Jakubechova J, Altanerova V, Zduriencikova M, Repiska V, Altaner C. Human mesenchymal stem cell-derived iron oxide exosomes enable focused ablation of tumor cells by way of magnetic hyperthermia. Int J Nanomedicine. 2017;12:7923–36.
Vázquez-Ríos AJ, Molina-Crespo Á, Bouzo BL, López-López R, Moreno-Bueno G, de la Fuente M. Exosome-mimetic nanoplatforms for focused most cancers drug supply. J Nanobiotechnol. 2019;17:85.
Zhao Q, Hai B, Kelly J, Wu S, Liu F. Extracellular vesicle mimics produced from iPS cell-derived mesenchymal stem cells enhance the therapy of metastatic prostate most cancers. Stem Cell Res Ther. 2021;12:29.
Severic M, Ma G, Pereira SGT, Ruiz A, Cheung CCL, Al-Jamal WT. Genetically-engineered anti-PSMA exosome mimetics concentrating on superior prostate most cancers in vitro and in vivo. J Management Launch. 2021;330:101–10.
